Prospective Study of Thrombospondin-1 Mimetic Peptides, ABT-510 and ABT-898, in Dogs with Soft Tissue Sarcoma

Journal of Veterinary Internal Medicine

Volumn 26, Issue 5, 2012, Pages 1169-1176

  Sahora, A I ^a   Rusk, A W ^b   Henkin, J ^c   McKeegan, E M ^c   Shi, Y ^c   Khanna, C ^a  

^a The Oncology Service LLC   (United States)

^b Animal Clinical Investigation LLC   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Anti angiogenesis; Case series; Circulating endothelial cells; Oncology; Translational study

Indexed keywords

ACETYL GLYCYL VALYL ALLO ISOLEUCYL SERYL GLUTAMINYL ISOLEUCYL ARGINYL PROLYL CYSTEINAMIDE; ACETYL-GLYCYL-VALYL-ALLO-ISOLEUCYL-SERYL-GLUTAMINYL-ISOLEUCYL-ARGINYL-PROLYL-CYSTEINAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOMIMETIC MATERIAL; NAC SAR GLY VAL (D ALLO ILE) THR NVA ILE ARG PRONET; NAC-SAR-GLY-VAL-(D-ALLO-ILE)-THR-NVA-ILE-ARG-PRONET; OLIGOPEPTIDE; THROMBOSPONDIN 1;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DOG; DOG DISEASE; FEMALE; MALE; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; SARCOMA; SOFT TISSUE TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; BLOOD CELL COUNT; COHORT STUDIES; DOG DISEASES; DOGS; FEMALE; MALE; OLIGOPEPTIDES; PROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; THROMBOSPONDIN 1;

ANIMALIA; CANIS FAMILIARIS;

EID: 84866341606     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2012.00966.x     Document Type: Article

References (41)

1. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-424.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000;21:505-515.
4. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003;4:277-289.
5. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-268.
6. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003;278:37632-37636.
7. Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007;74:90-99.
8. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 2001;78:663-672.
9. LaVallee TM, Zhan XH, Johnson MS, et al. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003;63:468-475.
10. Volpert OV, Alani RM. Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell 2003;3:199-200.
11. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-6628.
12. Dameron KM, Volpert OV, Tainsky MA, et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994;59:483-489.
13. Iruela-Arispe ML, Lombardo M, Krutzsch HC, et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999;100:1423-1431.
14. Miao WM, Seng WL, Duquette M, et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and-independent mechanisms. Cancer Res 2001;61:7830-7839.
15. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002;98:682-689.
16. Guo N, Krutzsch HC, Inman JK, et al. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997;57:1735-1742.
17. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-2846.
18. Gietema JA, Hoekstra R, de Fos FY, et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 2006;17:1320-1327.
19. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination. Eur J Cancer 2006;42:467-472.
20. Anderson JC, Grammer JR, Wang W, et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007;6:454-462.
21. Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007;67:1716-1724.
22. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26:5583-5588.
23. Ebbinghaus S, Hussain M, Tannir N, et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;13(22 Pt 1):6689-6695.
24. Khanna C, Lindblad-Toh K, Vail D, et al. The dog as a cancer model. Nat Biotechnol 2006;24:1065-1066.
25. Gordon I, Paoloni M, Mazcko C, et al. The comparative oncology trials consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982;5:649-655.
27. Rusk A, Cozzi E, Stebbins M, et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 2006;12:7456-7464.
28. Rusk A, McKeegan E, Haviv F, et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006;12:7444-7455.
29. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-156.
30. Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003;522:83-97.
31. Bertolini F, Shaked Y, Mancuso P, et al. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer 2006;6:835-845.
32. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-459.
33. Bertolini F, Mancuso P, Shaked Y, et al. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 2007;12:806-812.
34. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.
35. Shaked Y, Bocci G, Munoz R, et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005;5:551-559.
36. Wong CI, Koh TS, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27:4718-4726.
37. Wu H, Chen H, Hu PC. Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin Lab 2007;53:285-295.
38. Dawson DW, Volpert OV, Pearce SF, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999;55:332-338.
39. Withrow SJ, MacEwen EG. Small Animal Clinical Oncology, 4th ed. Philadelphia, PA: WB Saunders; 2007:425-442.
40. Simon R. Optimal two-stage designs for pre-clinical trials. Control Clin Trials 1989;10:1-10.
41. (VCOG) V. C.-o. O. G. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.